Literature DB >> 22393197

Melanoma.

Daniel G Coit, Robert Andtbacka, Christopher J Anker, Christopher K Bichakjian, William E Carson, Adil Daud, Raza A Dilawari, Dominick Dimaio, Valerie Guild, Allan C Halpern, F Stephen Hodi, Mark C Kelley, Nikhil I Khushalani, Ragini R Kudchadkar, Julie R Lange, Anne Lind, Mary C Martini, Anthony J Olszanski, Scott K Pruitt, Merrick I Ross, Susan M Swetter, Kenneth K Tanabe, John A Thompson, Vijay Trisal, Marshall M Urist.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22393197     DOI： 10.6004/jnccn.2012.0036

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  14 in total

Review 1.  The Evolution of Adjuvant Therapy for Melanoma.

Authors:  Justine V Cohen; Elizabeth I Buchbinder
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

Review 2.  Surgical treatment of melanoma patients with early sentinel node involvement.

Authors:  Rosemarie E Hardin; Julie R Lange
Journal:  Curr Treat Options Oncol       Date:  2012-09

3.  Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.

Authors:  Damon Reed; Ragini Kudchadkar; Jonathan S Zager; Vernon K Sondak; Jane L Messina
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

Review 4.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

Review 5.  The combination of checkpoint immunotherapy and targeted therapy in cancer.

Authors:  Niki Karachaliou; Maria Gonzalez-Cao; Aaron Sosa; Jordi Berenguer; Jillian Wilhelmina Paulina Bracht; Masaoki Ito; Rafael Rosell
Journal:  Ann Transl Med       Date:  2017-10

Review 6.  Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Authors:  Jason J Luke; F Stephen Hodi
Journal:  Oncologist       Date:  2013-05-24

7.  Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience.

Authors:  Manil Subesinghe; Maria Marples; Andrew F Scarsbrook; Jonathan T Smith
Journal:  Insights Imaging       Date:  2013-09-10

8.  MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor.

Authors:  Sara E Martin del Campo; Nicholas Latchana; Kala M Levine; Valerie P Grignol; Ene T Fairchild; Alena Cristina Jaime-Ramirez; Thao-Vi Dao; Volodymyr I Karpa; Mary Carson; Akaansha Ganju; Anthony N Chan; William E Carson
Journal:  PLoS One       Date:  2015-01-14       Impact factor: 3.240

9.  Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care.

Authors:  Annett Körner; Martin Drapeau; Brett D Thombs; Zeev Rosberger; Beatrice Wang; Manish Khanna; Alan Spatz; Adina Coroiu; Rosalind Garland; Gerald Batist
Journal:  BMC Dermatol       Date:  2013-03-01

10.  Predictors of skin self-examination before and after a melanoma diagnosis: the role of medical advice and patient's level of education.

Authors:  Annett Körner; Adina Coroiu; Claudia Martins; Beatrice Wang
Journal:  Int Arch Med       Date:  2013-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.